217 related articles for article (PubMed ID: 29111864)
1. Development of Acyclovir-Loaded Albumin Nanoparticles and Improvement of Acyclovir Permeation Across Human Corneal Epithelial T Cells.
Suwannoi P; Chomnawang M; Sarisuta N; Reichl S; Müller-Goymann CC
J Ocul Pharmacol Ther; 2017 Dec; 33(10):743-752. PubMed ID: 29111864
[TBL] [Abstract][Full Text] [Related]
2. Aqueous nanomicellar formulation for topical delivery of biotinylated lipid prodrug of acyclovir: formulation development and ocular biocompatibility.
Vadlapudi AD; Cholkar K; Vadlapatla RK; Mitra AK
J Ocul Pharmacol Ther; 2014 Feb; 30(1):49-58. PubMed ID: 24192229
[TBL] [Abstract][Full Text] [Related]
3. Acyclovir-Loaded Nanoemulsions: Preparation, Characterization and Irritancy Studies for Ophthalmic Delivery.
Mohammadi M; Elahimehr Z; Mahboobian MM
Curr Eye Res; 2021 Nov; 46(11):1646-1652. PubMed ID: 33979552
[No Abstract] [Full Text] [Related]
4. Development of a Novel Polymeric Nanocomposite Complex for Drugs with Low Bioavailability.
Sithole MN; Choonara YE; du Toit LC; Kumar P; Marimuthu T; Kondiah PPD; Pillay V
AAPS PharmSciTech; 2018 Jan; 19(1):303-314. PubMed ID: 28717975
[TBL] [Abstract][Full Text] [Related]
5. Transcorneal permeation of L- and D-aspartate ester prodrugs of acyclovir: delineation of passive diffusion versus transporter involvement.
Majumdar S; Hingorani T; Srirangam R; Gadepalli RS; Rimoldi JM; Repka MA
Pharm Res; 2009 May; 26(5):1261-9. PubMed ID: 18839288
[TBL] [Abstract][Full Text] [Related]
6. Development of solid lipid nanoparticles and nanostructured lipid carriers for improving ocular delivery of acyclovir.
Seyfoddin A; Al-Kassas R
Drug Dev Ind Pharm; 2013 Apr; 39(4):508-19. PubMed ID: 22424312
[TBL] [Abstract][Full Text] [Related]
7. Preparation and characterization of sodium ferulate entrapped bovine serum albumin nanoparticles for liver targeting.
Li FQ; Su H; Wang J; Liu JY; Zhu QG; Fei YB; Pan YH; Hu JH
Int J Pharm; 2008 Feb; 349(1-2):274-82. PubMed ID: 17870261
[TBL] [Abstract][Full Text] [Related]
8. Transport of acyclovir ester prodrugs through rabbit cornea and SIRC-rabbit corneal epithelial cell line.
Tak RV; Pal D; Gao H; Dey S; Mitra AK
J Pharm Sci; 2001 Oct; 90(10):1505-15. PubMed ID: 11745709
[TBL] [Abstract][Full Text] [Related]
9. Effect of chitosan, benzalkonium chloride and ethylenediaminetetraacetic acid on permeation of acyclovir across isolated rabbit cornea.
Majumdar S; Hippalgaonkar K; Repka MA
Int J Pharm; 2008 Feb; 348(1-2):175-8. PubMed ID: 17897799
[TBL] [Abstract][Full Text] [Related]
10. Ocular pharmacokinetics of acyclovir amino acid ester prodrugs in the anterior chamber: evaluation of their utility in treating ocular HSV infections.
Katragadda S; Gunda S; Hariharan S; Mitra AK
Int J Pharm; 2008 Jul; 359(1-2):15-24. PubMed ID: 18472234
[TBL] [Abstract][Full Text] [Related]
11. Nonpolymeric nanoassemblies for ocular administration of acyclovir: pharmacokinetic evaluation in rabbits.
Stella B; Arpicco S; Rocco F; Burgalassi S; Nicosia N; Tampucci S; Chetoni P; Cattel L
Eur J Pharm Biopharm; 2012 Jan; 80(1):39-45. PubMed ID: 22008147
[TBL] [Abstract][Full Text] [Related]
12. Amino acid prodrugs of acyclovir as possible antiviral agents against ocular HSV-1 infections: interactions with the neutral and cationic amino acid transporter on the corneal epithelium.
Anand BS; Katragadda S; Nashed YE; Mitra AK
Curr Eye Res; 2004; 29(2-3):153-66. PubMed ID: 15512962
[TBL] [Abstract][Full Text] [Related]
13. Development of etoposide-loaded bovine serum albumin nanosuspensions for parenteral delivery.
Wang Z; Li Z; Zhang D; Miao L; Huang G
Drug Deliv; 2015 Jan; 22(1):79-85. PubMed ID: 24401038
[TBL] [Abstract][Full Text] [Related]
14. Formulation of acyclovir-loaded solid lipid nanoparticles: 2. Brain targeting and pharmacokinetic study.
El-Gizawy SA; El-Maghraby GM; Hedaya AA
Pharm Dev Technol; 2019 Dec; 24(10):1299-1307. PubMed ID: 31507245
[TBL] [Abstract][Full Text] [Related]
15. Influence of drug loading and type of ointment base on the in vitro performance of acyclovir ophthalmic ointment.
Al-Ghabeish M; Xu X; Krishnaiah YS; Rahman Z; Yang Y; Khan MA
Int J Pharm; 2015 Nov; 495(2):783-91. PubMed ID: 26343911
[TBL] [Abstract][Full Text] [Related]
16. Targeted lipid based drug conjugates: a novel strategy for drug delivery.
Vadlapudi AD; Vadlapatla RK; Kwatra D; Earla R; Samanta SK; Pal D; Mitra AK
Int J Pharm; 2012 Sep; 434(1-2):315-24. PubMed ID: 22692074
[TBL] [Abstract][Full Text] [Related]
17. PEGylated Lipid Polymeric Nanoparticle-Encapsulated Acyclovir for In Vitro Controlled Release and Ex Vivo Gut Sac Permeation.
Mahmood S; Kiong KC; Tham CS; Chien TC; Hilles AR; Venugopal JR
AAPS PharmSciTech; 2020 Oct; 21(7):285. PubMed ID: 33057878
[TBL] [Abstract][Full Text] [Related]
18. Preparation of Bovine Serum Albumin (BSA) nanoparticles by desolvation using a membrane contactor: a new tool for large scale production.
Yedomon B; Fessi H; Charcosset C
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):398-405. PubMed ID: 23811438
[TBL] [Abstract][Full Text] [Related]
19. Ocular sustained release nanoparticles containing stereoisomeric dipeptide prodrugs of acyclovir.
Jwala J; Boddu SH; Shah S; Sirimulla S; Pal D; Mitra AK
J Ocul Pharmacol Ther; 2011 Apr; 27(2):163-72. PubMed ID: 21500985
[TBL] [Abstract][Full Text] [Related]
20. Topical application of acyclovir-loaded microparticles: quantification of the drug in porcine skin layers.
de Jalón EG; Blanco-Príeto MJ; Ygartua P; Santoyo S
J Control Release; 2001 Jul; 75(1-2):191-7. PubMed ID: 11451509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
